FYCOMPA® (perampanel) Oral Suspension Now Available as an Option for Patients with Epilepsy Who May Have Difficulty Swallowing Tablets or Prefer Liquids
/
/
FYCOMPA® (perampanel) Oral Suspension Now Available as an Option for Patients with Epilepsy Who May Have Difficulty Swallowing Tablets or Prefer Liquids

Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty swallowing tablets or prefer liquids. FYCOMPA CIII is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. This new option, which comes in a single bottle with an adapter and syringes to measure the right dose, was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2016. Please see Important Safety Information, including Boxed WARNING for Serious Psychiatric and Behavioral Reactions, below.

“Swallowing tablets can be a real concern for some patients with epilepsy,” saidLynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. “We are proud to offer this new option, which reinforces Eisai’s ongoing commitment to advancing epilepsy care and addressing the unmet medical needs of patients and their families.”
Share on social media:

Start typing and press Enter to search

Shopping Cart